Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)DivestmentsDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bio-Techne (TECH) Deferred Taxes (2016 - 2025)

Historic Deferred Taxes for Bio-Techne (TECH) over the last 17 years, with Q4 2025 value amounting to -$72000.0.

  • Bio-Techne's Deferred Taxes rose 9910.86% to -$72000.0 in Q4 2025 from the same period last year, while for Dec 2025 it was -$32.5 million, marking a year-over-year decrease of 634.04%. This contributed to the annual value of -$51.1 million for FY2025, which is 2955.86% down from last year.
  • Per Bio-Techne's latest filing, its Deferred Taxes stood at -$72000.0 for Q4 2025, which was up 9910.86% from $5.3 million recorded in Q3 2025.
  • In the past 5 years, Bio-Techne's Deferred Taxes ranged from a high of $5.4 million in Q3 2021 and a low of -$32.3 million during Q2 2025
  • For the 5-year period, Bio-Techne's Deferred Taxes averaged around -$6.8 million, with its median value being -$5.8 million (2021).
  • Its Deferred Taxes has fluctuated over the past 5 years, first skyrocketed by 129623.89% in 2021, then crashed by 258641.22% in 2023.
  • Over the past 5 years, Bio-Techne's Deferred Taxes (Quarter) stood at $1.8 million in 2021, then crashed by 187.51% to -$1.6 million in 2022, then plummeted by 571.03% to -$10.7 million in 2023, then rose by 24.68% to -$8.1 million in 2024, then surged by 99.11% to -$72000.0 in 2025.
  • Its last three reported values are -$72000.0 in Q4 2025, $5.3 million for Q3 2025, and -$32.3 million during Q2 2025.